News | January 12, 2026
Novartis to open Florida radioligand facility
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Subscribe To Our Newsletter & Stay Updated
